← VisionWave Holdings, Inc. (VWAVW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
VisionWave Holdings, Inc. (VWAVW)
Services-Prepackaged Software · market cap $2M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ad26.ZEBOV | Phase 3 | Ebola Virus Disease |
| AdvVEGF-D | Phase 2 | Refractory Angina Pectoris |
| BHVI1 eye drops | Phase 2 | Myopia |
| IVMED-80 | Phase 2 | Keratoconus |
| Intravitreous injection of ranibizumab | Phase 3 | High Risk Proliferative Diabetic Retinopathy |
| SHJ002 | Phase 2 | Corneal Erosion |
| rebamipide 2% ophthalmic suspension | Phase 3 | Keratoconjunctivitis Sicca |
| ACU-4429 | Phase 2 | Dry Age-related Macular Degeneration |
| Emixustat | Phase 2 | Stargardt Disease |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$0.05–$0.06
vs 50-day MA
—
vs 200-day MA
—
Realized vol
—
Max drawdown
-16.7%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VWAVW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.